GlaxoSmithKline | pharmaphorum

Tuesday 26 November 2024

Channels

Content type

Categories

Categories

Sort by

Order

GlaxoSmithKline

News

Medicago_facility

Medicago, GSK's plant-made COVID jab clears phase 2

Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 vaccine, partnered with GlaxoSmithKline, and is now hoping to have phase 3 data available "by e

News

Talking vaccines: Industry’s role in protecting the Gavi generation

Sanofi/GSK move latecomer COVID-19 shot into phase 3

Sanofi and GlaxoSmithKline seem to be getting somewhere with their COVID-19 vaccine at last, announcing plans to move to phase 3 following supportive mid-stage trial results.

News

scientifically visualization of a coronavirus spike protein

EU starts rolling review of GSK's antibody for COVID-19

The EMA has begun a rolling review of a COVID-19 antibody developed by GlaxoSmithKline and Vir BioTech which could become the fourth drug of its type cleared for early use in the EU.

News

GlaxoSmithKline (GSK)

GlaxoSmithKline focuses on split after lacklustre Q1 results

GlaxoSmithKline’s CEO Emma Walmsley said the company is focused on pursuing its strategy to spin off its consumer business after downbeat set of first quarter results.

News

gskhouse2

FDA approves under-pressure GSK's Jemperli for endometrial c...

The FDA has approved GlaxoSmithKline’s Jemperli (dostarlimab) immunotherapy, a drug acquired through its $5.1 billion acquisition of Tesaro, for certain patients with endometrial cancer.

News

scientifically visualization of a coronavirus spike protein

EMA starts review of GSK/Vir COVID-19 antibody

The EMA has started reviewing the emergency use application for GlaxoSmithKline and Vir Biotech's COVID-19 antibody VIR-7831, which could become the fourth drug of its type cleared for earl